Brokerages Expect Dermira Inc (NASDAQ:DERM) Will Announce Earnings of -$1.40 Per Share

Equities research analysts predict that Dermira Inc (NASDAQ:DERM) will report earnings per share (EPS) of ($1.40) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Dermira’s earnings, with the lowest EPS estimate coming in at ($1.48) and the highest estimate coming in at ($1.28). Dermira posted earnings per share of ($1.58) during the same quarter last year, which suggests a positive year-over-year growth rate of 11.4%. The business is scheduled to announce its next earnings report on Wednesday, November 6th.

According to Zacks, analysts expect that Dermira will report full year earnings of ($4.42) per share for the current fiscal year, with EPS estimates ranging from ($4.63) to ($4.15). For the next year, analysts expect that the business will report earnings of ($4.60) per share, with EPS estimates ranging from ($5.07) to ($3.82). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that cover Dermira.

Dermira (NASDAQ:DERM) last posted its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.57. Dermira had a negative net margin of 306.91% and a negative return on equity of 478.29%. The business had revenue of $66.65 million for the quarter, compared to analysts’ expectations of $34.16 million.

A number of research firms have recently commented on DERM. Needham & Company LLC reissued a “buy” rating and set a $22.00 target price on shares of Dermira in a research report on Friday, October 18th. BidaskClub raised shares of Dermira from a “strong sell” rating to a “sell” rating in a research report on Saturday. Finally, Zacks Investment Research raised shares of Dermira from a “hold” rating to a “strong-buy” rating and set a $6.50 target price on the stock in a research report on Wednesday, October 9th. Two analysts have rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $17.36.

In related news, CEO Thomas G. Wiggans purchased 23,419 shares of the company’s stock in a transaction that occurred on Monday, August 19th. The stock was acquired at an average price of $8.54 per share, for a total transaction of $199,998.26. Following the completion of the purchase, the chief executive officer now owns 39,666 shares in the company, valued at $338,747.64. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Matthew K. Fust sold 6,000 shares of Dermira stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $8.77, for a total transaction of $52,620.00. Following the completion of the sale, the director now owns 11,051 shares of the company’s stock, valued at approximately $96,917.27. The disclosure for this sale can be found here. 12.40% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of DERM. Point72 Hong Kong Ltd increased its stake in shares of Dermira by 124.2% in the second quarter. Point72 Hong Kong Ltd now owns 4,170 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 2,310 shares during the last quarter. Bank of Montreal Can increased its stake in Dermira by 621.8% during the second quarter. Bank of Montreal Can now owns 4,533 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 3,905 shares during the last quarter. Advisor Group Inc. increased its stake in Dermira by 41.7% during the second quarter. Advisor Group Inc. now owns 8,589 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 2,527 shares during the last quarter. Atria Investments LLC bought a new stake in Dermira during the second quarter valued at $85,000. Finally, Fox Run Management L.L.C. bought a new stake in Dermira during the second quarter valued at $120,000. Institutional investors and hedge funds own 94.51% of the company’s stock.

NASDAQ DERM opened at $7.35 on Friday. The company’s fifty day simple moving average is $7.17 and its 200-day simple moving average is $9.10. Dermira has a 52 week low of $5.25 and a 52 week high of $15.48. The company has a current ratio of 8.42, a quick ratio of 8.08 and a debt-to-equity ratio of 4.95. The stock has a market cap of $396.02 million, a P/E ratio of -1.40 and a beta of 1.32.

Dermira Company Profile

Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.

Recommended Story: What is a CD ladder?

Get a free copy of the Zacks research report on Dermira (DERM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.